Latest Impairment News

Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.

LTR Pharma has partnered with Strategic Drug Solutions to co-develop OROFLOW®, a novel intranasal spray aimed at providing fast symptom relief for Oesophageal Motility Disorders, tapping into a growing $4.5 billion global market.

Orica Limited reported a robust first half FY2025 with a 40% rise in NPAT pre-significant items and strong cash flow, underpinned by demand for premium blasting and digital solutions. The company also announced a $400 million share buy-back and a 32% higher interim dividend.

Orica Limited reported a 7.7% increase in revenue to $3.94 billion for the half year ended March 2025, but posted a net loss of $89 million due to significant impairment and restructuring charges. Excluding these items, net profit rose 40% to $250.8 million, with the board declaring a higher interim dividend.

ANZ Group Holdings Limited posted a 7% increase in statutory profit to AUD 3.642 billion for the half year ended 31 March 2025, with stable cash profit and an 83 cent interim dividend. The full integration of Suncorp Bank underpinned lending and deposit growth, while credit impairments eased.

Westpac Banking Corporation reported a 9% decline in net profit for the first half of 2025, reflecting margin compression and higher costs, while advancing its digital transformation and sustainability agenda.

National Australia Bank (NAB) reported steady cash earnings and improved return on equity in the first half of 2025, underpinned by strong capital ratios and a clear strategic focus on business banking, deposits, and proprietary home lending.

National Australia Bank posted a 0.8% rise in cash earnings for 1H25, underpinned by profit growth and lower credit impairments amid a cautious economic outlook. The bank advances its strategy focused on customer experience and technology modernization while maintaining strong capital and liquidity positions.

National Australia Bank’s half year results to March 2025 reveal modest revenue growth and stable cash earnings amid competitive pressures and regulatory demands. The bank’s strong capital position and ongoing strategy execution underpin cautious optimism.

Bega Group is consolidating its Strathmerton cheese operations into its Ridge Street site by mid-2026, targeting significant cost savings and operational efficiencies.

Aurizon reports a mixed freight volume performance to April 2025 alongside progress on $50 million in annualised cost savings and a potential subordinated hybrid capital raise.

Citigold Corporation Limited has faced intense ASX scrutiny following an adverse auditor opinion on its half-year financials, centering on a $20 million impairment of exploration assets. The company defends its valuation approach despite funding uncertainties and regulatory questions.